Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) – Research analysts at HC Wainwright boosted their FY2028 earnings per share estimates for shares of Compass Pathways in a report issued on Monday, November 9th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.10 for the year, up from their previous forecast of ($0.23). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Compass Pathways’ FY2029 earnings at $1.92 EPS and FY2030 earnings at $4.21 EPS.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.08.
A number of other brokerages have also recently issued reports on CMPS. Royal Bank Of Canada restated an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, November 4th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a research note on Tuesday, November 3rd. BTIG Research reiterated a “buy” rating and issued a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. Wells Fargo & Company dropped their target price on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and an average target price of $23.14.
Get Our Latest Stock Report on CMPS
Compass Pathways Stock Down 8.2%
Compass Pathways stock opened at $8.27 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average price of $11.79 and a 200-day moving average price of $10.47. Compass Pathways has a twelve month low of $4.88 and a twelve month high of $15.87. The company has a market capitalization of $1.17 billion, a P/E ratio of -2.37 and a beta of 2.43.
Institutional Investors Weigh In On Compass Pathways
Large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its stake in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after acquiring an additional 1,920 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares in the last quarter. Ancora Advisors LLC bought a new position in shares of Compass Pathways in the second quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Compass Pathways in the third quarter worth approximately $85,000. Finally, Entropy Technologies LP bought a new position in shares of Compass Pathways in the first quarter worth approximately $110,000. Institutional investors own 46.19% of the company’s stock.
About Compass Pathways
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
See Also
- Five stocks we like better than Compass Pathways
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
